Staff report on Sanofi's strategic use of third parties to influence the FDA
By: prepared by the staff of the Committee on Finance, United States Senate
Series: S. prt -- 112-20; S. prt -- 111-20.
Publisher: U.S. G.P.O.
Published: 2011
Place of publication: Washington
Language: eng
Format: [electronic resource] /
Number of pages: 177
Subjects: Corrupt practices; Management; Drug approval; Anticoagulants (Medicine); Government policy; Generic drugs; Sanofi aventis (Firm); United States. Food and Drug Administration; United States
Notes: Title from title screen (viewed on July 21, 2011).

At head of title: 112th Congress, 1st session. Committee print.

Paper version available for sale by the Supt. of Docs., U.S. G.P.O.

"May 2011."

Includes bibliographical references.